AR086356A1 - Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 - Google Patents
Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2Info
- Publication number
- AR086356A1 AR086356A1 ARP120101668A ARP120101668A AR086356A1 AR 086356 A1 AR086356 A1 AR 086356A1 AR P120101668 A ARP120101668 A AR P120101668A AR P120101668 A ARP120101668 A AR P120101668A AR 086356 A1 AR086356 A1 AR 086356A1
- Authority
- AR
- Argentina
- Prior art keywords
- diabetes
- treatment
- type
- pharmaceutical combination
- patients
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166052 | 2011-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086356A1 true AR086356A1 (es) | 2013-12-04 |
Family
ID=46052773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101668A AR086356A1 (es) | 2011-05-13 | 2012-05-11 | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130040878A1 (OSRAM) |
| EP (1) | EP2709652A1 (OSRAM) |
| JP (1) | JP6005140B2 (OSRAM) |
| KR (1) | KR20140041553A (OSRAM) |
| CN (2) | CN103648519A (OSRAM) |
| AR (1) | AR086356A1 (OSRAM) |
| AU (1) | AU2012257780B2 (OSRAM) |
| BR (1) | BR112013029256A8 (OSRAM) |
| CA (1) | CA2835336A1 (OSRAM) |
| MX (1) | MX356728B (OSRAM) |
| RU (2) | RU2017129878A (OSRAM) |
| WO (1) | WO2012156312A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3228320T3 (da) | 2008-10-17 | 2020-03-09 | Sanofi Aventis Deutschland | Kombination af et insulin og en glp-1-agonist |
| CN102711804B (zh) | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
| PL3417871T3 (pl) | 2009-11-13 | 2021-06-14 | Sanofi-Aventis Deutschland Gmbh | Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| RU2546520C2 (ru) | 2010-08-30 | 2015-04-10 | Санофи-Авентис Дойчланд Гмбх | Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| BR112014004726A2 (pt) | 2011-08-29 | 2017-04-04 | Sanofi Aventis Deutschland | combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| ES2687083T3 (es) * | 2013-01-17 | 2018-10-23 | Vtv Therapeutics Llc | Combinaciones de un agonista del GLPR1 y metformina y el uso de estos para el tratamiento de la diabetes tipo 2 y otros trastornos |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| AU2015205624A1 (en) | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| AU2015205620A1 (en) | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| SG11201604708VA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| ES2949095T3 (es) | 2014-12-12 | 2023-09-25 | Sanofi Aventis Deutschland | Formulación de relación fija de insulina glargina/lixisenatida |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| JP2023528726A (ja) | 2020-04-01 | 2023-07-06 | ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． | Ｇｌｐ１ｒアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法 |
| CN115461344B (zh) | 2020-04-01 | 2024-01-12 | 杭州中美华东制药有限公司 | 一种glp-1受体激动剂的晶型a及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| JP5980466B2 (ja) * | 2009-11-13 | 2016-08-31 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法 |
| PL2324853T3 (pl) * | 2009-11-13 | 2016-01-29 | Sanofi Aventis Deutschland | Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2 |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
-
2012
- 2012-05-10 US US13/468,422 patent/US20130040878A1/en not_active Abandoned
- 2012-05-11 RU RU2017129878A patent/RU2017129878A/ru not_active Application Discontinuation
- 2012-05-11 CN CN201280034724.7A patent/CN103648519A/zh active Pending
- 2012-05-11 KR KR1020137033311A patent/KR20140041553A/ko not_active Ceased
- 2012-05-11 WO PCT/EP2012/058779 patent/WO2012156312A1/en not_active Ceased
- 2012-05-11 CA CA2835336A patent/CA2835336A1/en not_active Abandoned
- 2012-05-11 EP EP12720196.0A patent/EP2709652A1/en not_active Withdrawn
- 2012-05-11 JP JP2014509759A patent/JP6005140B2/ja not_active Expired - Fee Related
- 2012-05-11 CN CN201810748089.8A patent/CN109045283A/zh active Pending
- 2012-05-11 RU RU2013155480/15A patent/RU2013155480A/ru unknown
- 2012-05-11 BR BR112013029256A patent/BR112013029256A8/pt not_active Application Discontinuation
- 2012-05-11 MX MX2013013198A patent/MX356728B/es active IP Right Grant
- 2012-05-11 AU AU2012257780A patent/AU2012257780B2/en not_active Ceased
- 2012-05-11 AR ARP120101668A patent/AR086356A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2835336A1 (en) | 2012-11-22 |
| KR20140041553A (ko) | 2014-04-04 |
| US20130040878A1 (en) | 2013-02-14 |
| CN109045283A (zh) | 2018-12-21 |
| RU2013155480A (ru) | 2015-06-20 |
| EP2709652A1 (en) | 2014-03-26 |
| BR112013029256A8 (pt) | 2018-01-16 |
| BR112013029256A2 (pt) | 2016-11-29 |
| MX2013013198A (es) | 2014-02-20 |
| MX356728B (es) | 2018-06-12 |
| WO2012156312A1 (en) | 2012-11-22 |
| RU2017129878A (ru) | 2019-02-05 |
| JP2014518860A (ja) | 2014-08-07 |
| CN103648519A (zh) | 2014-03-19 |
| AU2012257780B2 (en) | 2017-06-01 |
| JP6005140B2 (ja) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| BR112013019744A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2 | |
| AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| BR112013024973A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2 | |
| CU20110100A7 (es) | Tratamiento de pirfenidona para pacientes con función hepática atípica | |
| CY1119582T1 (el) | Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| PE20140872A1 (es) | Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple | |
| BR112013004756A2 (pt) | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 | |
| CY1117603T1 (el) | Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2 | |
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| CR20110243A (es) | Tratamiento de pirfenidona para pacientes con función hepática. | |
| CY1113755T1 (el) | Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2 | |
| MX344303B (es) | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. | |
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| CL2012002437A1 (es) | Uso de antiinflamatorio no esteroide (aine) o una sal farmacologicamente aceptable del mismo para preparar un medicamento util para el tratamiento de enfermedades renales cronicas en gatos. | |
| BR112017006272A2 (pt) | composição farmacêutica para tratar colite ulcerativa. | |
| MX389091B (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2. | |
| AR084093A1 (es) | Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |